Does a GLP-1 Cause Acne, or Does Losing Weight?

The short version

If your skin got worse after starting a GLP-1, the question that matters is not whether to blame the drug. It is what actually changed, because the answer points at different fixes.

The direct evidence is reassuring and thin at the same time. A 2024 meta-analysis in the International Journal of Women's Dermatology looked for an acne signal across the long-acting agonists — dulaglutide, extended-release exenatide, and semaglutide as Wegovy — and the short-acting ones, liraglutide, lixisenatide and semaglutide as Rybelsus. It found no conclusive acne side effects reported for any of them, and concluded that it is unlikely the drugs themselves are directly responsible. Its own stated limitation is that there is not much literature to pool¹.

So: no established drug effect, on evidence that is genuinely limited. What follows is the part worth your attention.

What did change is what you eat

Diet is one of the few things about acne with real trial support behind it, and a GLP-1 changes diet by design.

A systematic review of 34 studies drawn from 410 screened found that high glycemic index and increased glycemic load are positively associated with acne and its severity, supported by randomized controlled trials. The dairy picture was mixed and appeared to depend on sex, ethnicity and dietary culture; the glycemic finding was the consistent one, described as a modest but significant proacnegenic effect².

That cuts both ways on these drugs, which is why it is interesting rather than alarming. Appetite suppression usually pushes people toward less refined carbohydrate — which the evidence above would predict improves skin. But it also pushes some people toward whatever is quick and tolerable when nausea is bad, and toward protein shakes. If your intake shifted in that direction, the diet literature predicts the opposite result.

Neither outcome is the molecule acting on your skin. Both are your diet acting on your skin, arriving through a prescription.

The hormonal route, which matters more if you have PCOS

The other plausible path is androgens, and it is the one most likely to be relevant to readers of this site.

A 2026 paper examined GLP-1 agonists specifically against acne, hidradenitis suppurativa and sebaceous activity — the oil-gland behavior that sits underneath acne³. Sebum production is androgen-driven, and androgens are exactly what shifts when weight and insulin resistance shift. If you have PCOS, that shift is the thing you were hoping for, and skin is one of the places it shows up. Our PCOS evidence page covers what these drugs do to that picture.

The direction is not guaranteed. Falling insulin resistance would generally be expected to help androgen-driven acne, but hormonal systems in transition do not always move in a straight line, and nobody has measured this specific sequence in this specific population.

What this is not

It is not the hair thing. Rapid weight loss can push a batch of follicles into shedding a couple of months later, which is a real, documented and self-limiting phenomenon — but it is a different mechanism with a different timeline, and it is covered on hair loss on GLP-1s. Do not reason from one to the other.

It is also not "Ozempic face", which is volume loss rather than a skin condition. That is its own page.

What actually treats it

Acne has a strong, current, guideline-backed treatment literature that has nothing to do with any of the above — which is the practical good news. The American Academy of Dermatology's 2024 guideline issues 18 evidence-based recommendations and 5 good-practice statements⁴.

Two things follow for a reader on a GLP-1. The hormonal options in that last row are the ones most likely to fit androgen-driven adult acne, and they are a prescribing conversation rather than a shelf purchase. And combining topicals with different mechanisms is standard practice, so a single product failing is not evidence that nothing will work.

If you are pregnant, trying to conceive, or breastfeeding, several of these are off the table entirely — isotretinoin absolutely, and the hormonal options need their own discussion. That belongs with whoever manages your prescription, not with a general guideline.

Where this sits on the evidence scale

A direct drug effect on acne: not established, on limited evidence. One meta-analysis across six agonists found no conclusive signal and said the literature is thin. Absence of a finding in a small literature is weaker than a finding of absence.

Glycemic load worsens acne: moderate to strong. A systematic review of 34 studies with randomized trial support, and the mechanism most likely to explain a real-world change on these drugs.

The androgen and sebaceous route: low. Biologically coherent, examined in a 2026 paper, and not measured as a sequence in people starting these drugs.

Treatment: strong. A current specialty-society guideline with 18 graded recommendations. Whatever caused it, the treatments are the same ones that have always worked.